Skip to main content

Table 1 Patients characteristics at baseline

From: Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors

Variable Non-switchers (n = 69) Switchers (n = 48) P
Male gender 61/69 (88.4%) 38/48 (79.2%) 0.199
Age, years 37.3 ± 13.2 38.3 ± 11.2 0.665
HLA-B27 positivity 38/46 (82.6%) 34/40 (85.0%) 1.000
Smoking 17/45 (37.8%) 13/36 (36.1%) 1.000
Disease duration, years 11.4 (6.2, 17.7) 9.2 (5.7, 19.2) 0.840
Peripheral involvement 45/69 (65.2%) 37/48 (77.1%) 0.218
Pure axial involvement 24/69 (34.8%) 11/48 (22.9%) 0.218
BASDAI 5.2 ± 2.0 5.5 ± 2.1 0.482
BASFI 5.2 ± 2.5 5.9 ± 2.4 0.199
BASMI 3.9 ± 2.8 4.5 ± 2.7 0.290
ASQoL 10.4 ± 5.5 12.7 ± 4.7 0.058
CRP, mg/l 21.6 (12.8, 38.0) 20.6 (12.6, 40.0) 0.397
ESR, mm/hr 20.5 (11.0, 34.5) 25.0 (13.1, 48.5) 0.268
ASDAS – CRP 3.8 ± 0.9 3.9 ± 1.0 0.714
ASDAS – ESR 3.3 ± 0.9 3.6 ± 1.0 0.175
Concomitant use of:
 NSAID 50/69 (72.4%) 41/48 (85.4%) 0.117
 DMARD 62/69 (88.9%) 35/48 (72.9%) 0.023*
 SSZ only 26/69 (37.7%) 9/48 (18.8%) 0.039*
 MTX only 13/69 (18.8%) 8/48 (16.7%) 0.811
 Cyclosporine 1/69 (1.4%) 1/48 (2.1%) 1.000
 Leflunomide 7/69 (10.1%) 8/48 (16.7%) 0.400
 Prednisone 23/69 (33.3%) 15/48 (31.2%) 0.844
  1. Values are expressed as mean (SD), median (quartile) and percentages. BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, ASQoL Ankylosing Spondylitis Quality of Life, CRP C Reactive Protein, ESR Erythrocyte Sedimentation Rate, ASDAS Ankylosing Spondylitis Disease Activity Score, NSAID Non-steroidal Anti-Inflammatory Drug, SSZ Sulfasalazine, MTX Methotrexate, *P < 0.05